Published online Sep 18, 2014. doi: 10.5312/wjo.v5.i4.504
Revised: March 26, 2014
Accepted: May 31, 2014
Published online: September 18, 2014
Core tip: Tofacitinib, a Janus kinase inhibitor, is a targeted, synthetic, disease-modifying antirheumatic drug (DMARD) approved for the treatment of moderately to severely active rheumatoid arthritis in patients who have had an inadequate response to methotrexate. In numerous phase 2 and 3 trials, tofacitinib has proven to be safe and effective as monotherapy or in combination with methotrexate or other non-biologic DMARDs.